BMO Capital Retains Bullish Stance on Intercept Pharmaceuticals (ICPT) Following Q3 Results, FLINT Data
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $515 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following in-line ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
